MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead

   MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of
        Directors And Appointment Of Christine White As Lead Director

PR Newswire

SAN DIEGO, Jan. 30, 2013

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ --MEI Pharma, Inc. (Nasdaq: MEIP), an
oncology company focused on the clinical development of novel therapies for
cancer, announced today that Professor Bryan R.G. Williams, Ph.D., will not
stand for re-election to MEI Pharma's Board of Directors upon the expiration
of his term at the Company's next Annual Meeting of Stockholders. Professor
Williams has been a member of the Board since March 2006 and has served as
Chairman since November 2006.

(Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

"It has been a tremendous experience working with the Board and management
team of MEI Pharma," said Professor Williams. "My decision to retire from the
Board is driven in part by my increasing responsibilities as Director of the
Monash Institute of Medical Research in Melbourne. I also believe that this is
the right time to hand over the leadership of the Board to a successor with
extensive drug development experience as the Company advances its drug
candidates into later stage clinical testing. I wish the Company and its
shareholders continued success in the future."

"It has been a pleasure and a great honor to have served with Bryan," said
Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma.
"Bryan's leadership on the board was critical during the Company's transition
from R&D to clinical development and he has been a source of strength for our
Board over the course of the past seven years. On behalf of all of us, I would
like to thank him for the significant contributions he has made to the
Company. I am confident that we will find a qualified and proven successor as
Chairman to help us continue in the strategic direction that Bryan helped to
put in place."

Effective upon Professor Williams' retirement, Christine A. White, M.D., will
serve as Lead Director until a new Chairman has been appointed. The Board's
Nomination Committee has commenced a process to select a successor, reviewing
both internal and external candidates, including consideration of candidates
proposed by new investors Vivo Ventures and New Leaf Ventures.

"Christine is a highly experienced director and well suited for this role. Her
guidance will help to ensure a smooth transition and provide the Board time to
identify an ideal candidate for the next stage of our Company's growth," Dr.
Gold added. "In addition, her knowledge of oncology drug development and
regulatory affairs coupled with her experience as a clinical oncologist
continue to pay dividends as we diligently prepare for the initiation of
several Phase II clinical trials in the months ahead."

Dr. White was appointed as a director in August 2010. She was with Biogen Idec
from 1996 to 2005, most recently as Senior Vice President, Global Medical
Affairs, where she played an integral role in the clinical development,
regulatory affairs and commercialization of oncology drugs Rituxan^® and
Zevalin^®. Dr. White also serves as a member of the board of directors of
Arena Pharmaceuticals. Dr. White earned her B.A. in Biology and her M.D. from
the University of Chicago and is Board certified in both Internal Medicine and
Medical Oncology.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused
on the clinical development of novel therapies for cancer. The Company's lead
drug candidate is Pracinostat, a potential best-in-class, oral histone
deacetylase (HDAC) inhibitor being developed for advanced hematologic
malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia
(AML). Results from a pilot Phase II clinical trial of Pracinostat in
combination with azacitidine in patients with advanced MDS showed an overall
response rate (CR+CRi+PR) of 90% (nine out of 10), including eight complete
responses. The Company plans to initiate a randomized, placebo-controlled
Phase II trial of Pracinostat in combination with azacitidine in patients with
MDS by June 2013. In addition, MEI Pharma is developing two drug candidates
derived from its isoflavone-based technology platform, ME-143 and ME-344. For
more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated
in clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain
market acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.

SOURCE MEI Pharma, Inc.

Website: http://www.meipharma.com
Contact: Pete De Spain, Sr. Director, Investor Relations & Corporate
Communications, +1-858-792-3729, pdespain@meipharma.com
 
Press spacebar to pause and continue. Press esc to stop.